MedTrace Logo

Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting

NCT04370782 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2020-12-09

No results posted yet for this study

Summary

This is a randomized, open-label trial to assess the safety and efficacy of hydroxychloroquine, and zinc in combination with either azithromycin or doxycycline in a higher risk COVID-19 positive outpatient population.

Conditions

Interventions

DRUG

Hydroxychloroquine

Hydroxychloroquine 400mg twice a day (BID) on day 1, followed by 200mg BID for days 2-5

DRUG

Azithromycin

Azithromycin 500mg on day 1, followed by 250mg once daily for days 2-5

DRUG

Zinc Sulfate

Zinc sulfate 220mg once daily for 5 days

DRUG

Doxycycline

Doxycycline 200 mg once daily for 5 days

Sponsors & Collaborators

  • St. Francis Hospital, New York

    lead OTHER

Principal Investigators

  • Avni Thakore, MD · Saint Francis Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-28
Primary Completion
2020-09-30
Completion
2020-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04370782 on ClinicalTrials.gov